Methods and compositions for prognosis and treatment of cancers
AssigneeGenentech, Inc.
InventorsLuciana Molinero, Priti Hegde
Life of this patent
Estimating the term…
Abstract
The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer.
Claims13
A method of selecting treating a human patient having non-squamous non-small cell lung cancer (NSCLC), the method comprising:
- (i) determining the expression level of an immune cell gene signature in a tumor sample obtained from the patient, the immune cell gene signature comprising the following gene signature set:
- ITGAM, ITGAX, CD1C, and CLEC4C
- wherein an increase in the level of expression of each member of the immune cell gene signature relative to a median level identifies the patient for treatment with an immunotherapy;
- and
- (ii) administering the immunotherapy to the patient.
A method of treating a human patient having non-squamous NSCLC, the method comprising administering an immunotherapy to the patient, wherein the expression level of an immune cell gene signature in a tumor sample obtained from the patient has been determined to have an increase in the level of expression of each member of the immune cell gene signature relative to a median level, the immune cell gene signature comprising the following gene signature set:
- ITGAM, ITGAX, CD1C, and CLEC4C.
Dependencies are inferred from the claim text.